ABO blood group and risk of COVID-19 infection and complications: A systematic review and meta-analysis

Marta Gutiérrez-Valencia, Leire Leache, Julián Librero, Carlos Jericó, Mónica Enguita Germán, Jose Antonio García-Erce, Marta Gutiérrez-Valencia, Leire Leache, Julián Librero, Carlos Jericó, Mónica Enguita Germán, Jose Antonio García-Erce

No abstract available

Keywords: ABO blood group; COVID-19; meta-analysis; systematic review.

Conflict of interest statement

The authors have disclosed no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Preferred Reporting Items for Systematic Reviews and Meta‐Analyses statement (PRISMA) flow diagram [Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 2
FIGURE 2
Forest plot for coronavirus disease 2019 (COVID‐19) infection. 1. O versus non‐O; 2. A versus non‐A; and 3. B versus non B [Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 3
FIGURE 3
Forest plot for mortality. 1. O versus non‐O; 2. A versus non‐A; and 3. B versus non‐B [Color figure can be viewed at wileyonlinelibrary.com]

References

    1. WHO World Health Organization (WHO) Coronavirus (COVID‐19) Dashboard.
    1. Li X, Zhong X, Wang Y, Zeng X, Luo T, Liu Q. Clinical determinants of the severity of COVID‐19: a systematic review and meta‐analysis. PLoS One. 2021;16:e0250602.
    1. SeyedAlinaghi S, Mehrtak M, MohsseniPour M, MirzaPour P, Barzegary A, Habibi P, et al. Genetic susceptibility of COVID ‐ 19: a systematic review of current evidence. Eur J Med Res. 2021;26:46.
    1. Pijls BG, Jolani S, Atherley A, Derckx RT, Dijkstra JIR, Franssen GHL, et al. Demographic risk factors for COVID‐19 infection, severity, ICU admission and death: a meta‐analysis of 59 studies. BMJ Open. 2021;11:e044640.
    1. Goel R, Bloch EM, Pirenne F, Al‐Riyami AZ, Crowe E, Dau L, et al. ABO blood group and COVID‐19: a review on behalf of the ISBT COVID‐19 working group. Vox Sang. 2021;116:849–61.
    1. Yildirim Z, Sahin OS, Yazar S, Bozok CV. Genetic and epigenetic factors associated with increased severity of Covid‐19. Cell Biol Int. 2021;45:1158–74.
    1. Liu N, Zhang T, Ma L, Zhang H, Wang H, Wei W, et al. The impact of ABO blood group on COVID‐19 infection risk and mortality: a systematic review and meta‐analysis. Blood Rev. 2020;48:100785.
    1. Bhattacharjee S, Banerjee M, Pal R. ABO blood groups and severe outcomes in COVID‐19: a meta‐analysis. Postgrad Med J. 2020. 10.1136/postgradmedj-2020-139248.
    1. Golinelli D, Boetto E, Maietti E, Fantini MP. The association between ABO blood group and SARS‐CoV‐2 infection: a meta‐analysis. PLoS One. 2020;15:e0239508.
    1. Kabrah SM, Kabrah AM, Flemban AF, Abuzerr S. Systematic review and meta‐analysis of the susceptibility of ABO blood group to COVID‐19 infection. Transfus Apher Sci. 2021;60:103169.
    1. Franchini M, Cruciani M, Mengoli C, Marano G, Candura F, Lopez N, et al. ABO blood group and COVID‐19: an updated systematic literature review and meta‐analysis. Blood Transfus. 2021;19:317–26.
    1. Riley RD, Moons KGM, Snell KIE, Ensor J, Hooft L, Altman DG, et al. A guide to systematic review and meta‐analysis of prognostic factor studies. BMJ. 2019;364:k4597.
    1. Rayyan‐Intelligent Systematic Review [Internet]. Available from:
    1. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group . Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
    1. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle‐Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta‐analyses.
    1. Schünemann H, Brożek J, Guyatt G, Oxman A. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. Updated 2013. Available from:
    1. Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
    1. Kolin DA, Kulm S, Christos PJ, Elemento O. Clinical, regional, and genetic characteristics of Covid‐19 patients from UK Biobank. PLoS One. 2020;15:e0241264.
    1. The Severe Covid‐19 GWAS Group . Genomewide association study of severe Covid‐19 with respiratory failure. N Engl J Med. 2020;383:1522–34.
    1. Muñiz‐Diaz E, Llopis J, Parra R, Roig I, Ferrer G, Grifols J, et al. Relationship between the ABO blood group and COVID‐19 susceptibility, severity and mortality in two cohorts of patients. Blood Transfus. 2021;19:54–63.
    1. Apea VJ, Wan YI, Dhairyawan R, Puthucheary ZA, Pearse RM, Orkin CM, et al. Ethnicity and outcomes in patients hospitalised with COVID‐19 infection in East London: an observational cohort study. BMJ Open. 2021;11:e042140.
    1. Wu BB, Gu DZ, Yu JN, Yang J, Wang‐Qin S. Association between ABO blood groups and COVID‐19 infection, severity and demise: a systematic review and meta‐analysis. Infect Genet Evol. 2020;84:104485.
    1. Pourali F, Afshari M, Alizadeh‐Navaei R, Javidnia J, Moosazadeh M, Hessami A. Relationship between blood group and risk of infection and death in COVID‐19: a live meta‐analysis. New Microbes New Infect. 2020;37:100743.
    1. Cheng Y, Cheng G, Chui CH, Lau FY, Chan PKS, Ng MHL, et al. ABO blood group and susceptibility to severe acute respiratory syndrome. JAMA. 2005;293:1450–1.
    1. Guillon P, Clément M, Sébille V, Rivain JG, Chou CF, Ruvoën‐Clouet N, et al. Inhibition of the interaction between the SARS‐CoV spike protein and its cellular receptor by anti‐histo‐blood group antibodies. Glycobiology. 2008;18:1085–93.
    1. Connors JM, Levy JH. COVID‐19 and its implications for thrombosis and anticoagulation. Blood. 2020;135:2033–40.
    1. Franchini M, Capra F, Targher G, Montagnana M, Lippi G. Relationship between ABO blood group and von Willebrand factor levels: from biology to clinical implications. Thromb J. 2007;5:14.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner